Abstract:For patients affected by severe inherited platelet dysfunctions, e.g. Glanzmann thrombasthenia (GT) or Bernard-Soulier syndrome (BSS), platelet transfusion is frequently needed for controlling spontaneous bleeding, and is always needed when trauma occurs or surgery is performed. For the mild-to-moderate bleeding entities, e.g. storage pool disease, thrombaxane A2 receptor defect, platelet transfusion is usually unnecessary. Transfusion of platelets should be used selectively and sparingly because of the substantial risk of alloimmunization against HLA antigens and/or platelet glycoproteins (GP) αIIb, β(3), or αIIbβ(3) in GT, and GPI-IX-V in BSS, which may lead to refractoriness to therapy. To reduce the risk, HLA-matched single donors of platelets should be used. If such donors are unavailable, leucocyte-depleted blood components should be used. Therapy other than platelet transfusion includes: (i) Prevention (vaccination against hepatitis B, avoidance of non-steroidal anti-inflammatory drugs, preservation of dental hygiene, correction of iron deficiency and prenatal diagnosis). (ii) Topical measures (compression with gauze soaked with tranexamic acid, fibrin sealants, splints for dental extractions and packing for nose bleeds). (iii) Antifibrinolytic agents that are useful for minor surgery and as adjuncts for other treatment modalities. (iv) Desmopressin that increases plasma levels of von Willebrand factor and factor VIII giving rise to increased platelet adhesiveness and aggregation associated with shortened bleeding time. (v) Recombinant factor VIIa (rFVIIa). GT patients have been treated for bleeding episodes by rFVIIa with partial success. The mechanism by which rFVIIa arrests bleeding is probably related to increased thrombin generation by a tissue factor-independent process, enhanced platelet adhesion and restoration of platelet aggregation. (vi) Female hormones. Excessive bleeding during menarche in patients with GT or BSS can be controlled by high doses of oestrogen followed by high doses of oral oestrogen-progestin. Menorrhagia later in life can be managed by continuous oral contraceptives. Depo-medroxyprogesterone acetate administered every 3 months is an alternative when combined oral contraceptives are contraindicated.

How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease

von Willebrand disease

Retrospective chart review of GI bleeding in people with von Willebrand disease

Diagnosis and treatment of von Willebrand disease in 2024 and beyond

Current and emerging therapies as potential treatment for people with von Willebrand disease

von Willebrand disease: A guide for the internist

Von Willebrand Disease and Angiodysplasia: a wider view of pathogenesis in pursuit of therapy

Progress in von Willebrand Disease Treatment: Evolution towards Newer Therapies

The diagnosis, natural history, and management of von Willebrand disease in women in the age of guidelines

Treatment of inherited platelet disorders

Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD

Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N

How I Treat Bleeding in Hereditary Hemorrhagic Telangiectasia

Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what's new on the horizon?

Acquired bleeding disorders

Perioperative hemostasis management in patients with von Willebrand disease: an institutional experience

Efficacy of emicizumab therapy in two adult patients with type 3 von Willebrand disease

von Willebrand disease: what does the future hold?

Rare bleeding disorders: Advances in management

A rare case of acquired von Willebrand syndrome type 2B: diagnosis, treatment, and underlying pathophysiology

Variceal hemorrhage in a patient with cirrhosis and congenital hemophilia A: A therapeutic challenge